CMS Projects Billions in Future Savings for Seniors; Maximum Fair Price (MFP) Negotiation Policy Originated Under Biden Administration | iPharmaCenter
The Centers for Medicare & Medicaid Services (CMS) announced a projected net savings of 44%, or $12 billion, on 15 widely used drugs for cancer and other chronic conditions, building on efforts to make prescriptions more affordable for Medicare beneficiaries. Under the Maximum Fair Price (MFP) negotiation policy, established as part of the Biden administration’s Inflation Reduction Act, CMS has negotiated lower prices for high-cost drugs, with these new prices set to take ef
CMS Introduces Proposed Rule to Elevate Quality and Access in Medicare Advantage and Part D | iPharmaCenter
The Centers for Medicare & Medicaid Services (CMS) has proposed new policies for Medicare Advantage (MA) and Medicare Part D plans, aiming to improve quality, boost access, and support innovative benefit designs. The 2027 draft rule details significant changes to the Star Ratings system and invites public comments on how to further modernize Medicare Advantage for both beneficiaries and taxpayers. Also read: Top 10 pharmaceutical companies by revenues Under these proposed u
NICE Approves Autolus’ Obe-cel CAR-T Therapy for Adults with Rare Blood Cancer | iPharmaCenter
Hundreds of adults in England living with a rare and aggressive form of blood cancer could soon access a potentially life-saving therapy, following new guidance from the National Institute for Health and Care Excellence (NICE). NICE has recommended obecabtagene autoleucel, also known as obe-cel or Aucatzyl, for routine NHS use in patients aged 26 and over with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL). The decision marks an important step forward for
Novartis Receives FDA Approval for Itvisma, Expanding Access to Gene Replacement Therapy for People of All Ages Living with Spinal Muscular Atrophy (SMA)
East Hanover, N.J., [November 24, 2025] - Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Itvisma (onasemnogene abeparvovec) for the treatment of children two years and older, as well as adolescents and adults living with spinal muscular atrophy (SMA) with a confirmed mutation in the survival motor neuron 1 (SMN1) gene. This approval makes Itvisma the first and only gene replacement therapy available for this broad population of people a
The Pharma Top 10: Highest Revenue Drugs of 2025 (Official Sales Data & Analysis) | Top selling pharmaceutical drugs | iPharmaCenter
Get the definitive ranking of the top-selling pharmaceutical drugs by global revenue in 2025. See which blockbusters—from Keytruda to the GLP-1 therapies like Ozempic and Mounjaro—are leading the market and driving record sales in Oncology and Immunology.
Germany Signals Major Health System Overhaul as Minister Warken Warns of Growing Deficits | iPharmaCenter
Germany’s Federal Health Minister Nina Warken has signaled significant reforms to the country’s healthcare system, stressing that structural changes are unavoidable as statutory health insurance (GKV) faces mounting financial pressure